At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Nov 5, 2026 at 23:18 ET
Inovio priced a $75M underwritten public offering of 58.7M shares at $1.05/share plus pre-funded warrants, following the October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP. The offering from the $300M shelf, underwritten by Jefferies and Piper Sandler, represents ~34% dilution based on shares outstanding before the offering, underscoring ongoing capital needs for a pre-revenue biotech with a going concern warning.
- Priced 58,747,235 shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049 each
- Gross proceeds expected ~$75M before underwriting discounts and commissions
- Underwriters have 30-day option to purchase up to 10,714,285 additional shares
- Offering expected to close on or about November 9, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access